COGT today
$29.40-$2.24 (-7.08%)close Nov 11, 2026Trend
DailyUptrend (starting)
4 hourBearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bullish
Daily trend turns down below $27.73
Key levels
Resistance$32.03
Resistance$29.69
Support$27.73
Latest news & SEC filings
AnalystHC Wainwright & Co. raises Cogent Biosciences price target
AnalystHC Wainwright keeps Buy rating on Cogent Biosciences, lifts target to $56
EarningsCogent Biosciences Posts Q3 2026 Results
All COGT news →About Cogent Biosciences
Cogent Biosciences is a clinical-stage biotechnology company that creates targeted medicines for illnesses driven by specific genetic mutations. Its main candidate, bezuclastinib, is a KIT inhibitor in development for systemic mastocytosis and gastrointestinal stromal tumors. The company also has early-stage programs aimed at FGFR2/3, ErbB2, PI3K alpha, KRAS, and JAK2. It is based in the United States, with research operations in Boulder, Colorado.
Based on the company's 10-K filed Feb 17, 2026.
Nasdaq · Healthcare
Cogent Biosciences, Inc. (COGT)
What Is the Price Target for COGT?
SEPT Low Target
$52.00
SEPT Mid Target
$55.00
SEPT High Target
$56.00
Analyst Consensus
$55.00
Is COGT a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for COGT.
Start Free Trial →Is COGT Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$43.08
10
Moat Score
NONE
3/9
Piotroski Score
5.7
Altman Z-Score
What Is Smart Money Doing with COGT?
Insider Signal
NEUTRAL
0 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Morris Arlene | director | Buy | 41,927 | $236K | Aug 27, 2026 |
| Morris Arlene | director | Buy | 3,583 | $9K | Aug 27, 2026 |
| Morris Arlene | director | Sale | 42,349 | $1.6M | Aug 27, 2026 |
| Morris Arlene | director | Sale | 3,161 | $119K | Aug 27, 2026 |
| Robbins Andrew R | director officer | Sale | 160,000 | - | May 19, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →COGT Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-11.34%
FCF Growth YoY
-27.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for COGT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for COGT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:36 | $29.40 | 1,056 | $$31K | SELL |
| 21:00:21 | $29.40 | 2,963 | $$87K | SELL |
| 21:00:21 | $29.40 | 1,900 | $$56K | SELL |
| 21:00:21 | $29.40 | 6,100 | $$179K | SELL |
| 21:00:20 | $29.40 | 5,600 | $$165K | SELL |
5 dark pool trades shown · $$518K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for COGT
PREVIEWSEPT Investing provides real-time options flow tracking for COGT, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $25 | Dec 18 | 37 | $$500 | 5 | SWEEP |
| CALL | $35 | Dec 18 | 37 | $$70.6K | 588 | BLOCK |
| CALL | $40 | Dec 18 | 37 | $$20.6K | 588 | BLOCK |
| CALL | $30 | Jan 15 | 65 | $$380 | 1 | SWEEP |
| CALL | $30 | Dec 18 | 37 | $$241 | 1 | SWEEP |
5 options trades shown · 80% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Cogent Biosciences, Inc. (COGT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →COGT — frequently asked questions
What is COGT stock price today?
Cogent Biosciences, Inc. (COGT) is at $29.40, down 7.08% (-$2.24) at the Nov 11, 2026 close.
Why is COGT stock moving today?
Latest COGT news — Nov 9, 2026: HC Wainwright & Co. raises Cogent Biosciences price target · Nov 9, 2026: HC Wainwright keeps Buy rating on Cogent Biosciences, lifts target to $56
What is the COGT price target?
The average analyst price target for COGT is $55.00, ranging from $52 to $56, based on 4 analysts. Latest: HC Wainwright & Co. maintains on Nov 9, 2026.
What do analysts rate COGT?
Analyst ratings for COGT: 11 Buy, 1 Hold, 0 Sell — consensus Strong Buy.
Did COGT beat earnings?
COGT last reported on Aug 10, 2026: EPS -$0.96.
Does COGT pay a dividend?
COGT does not currently pay a dividend.
How much debt does COGT have?
Cogent Biosciences, Inc. reported $224M of debt and $217M of cash (Sep 30, 2026).
What are COGT support and resistance levels?
Support: $27.73. Resistance: $29.69, $32.03, $35.00.
What are insiders doing with COGT?
Insider activity: NEUTRAL, 0 buys and 3 sells in the last 90 days.
What is the latest news on COGT?
Nov 9, 2026: HC Wainwright & Co. raises Cogent Biosciences price target · Nov 9, 2026: HC Wainwright keeps Buy rating on Cogent Biosciences, lifts target to $56 · Nov 5, 2026: Cogent Biosciences Posts Q3 2026 Results